Sanofi India Ltd vs Sotac Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3407 as of 30 Apr 15:30 . The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 6 quarters. This represents a CAGR of -100.00% The p/e ratio of Sotac Pharmaceuticals Ltd changed from 31.3 to 16.4 over 2 quarters. This represents a CAGR of -72.55% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of -100.00% The market cap of Sotac Pharmaceuticals Ltd changed from ₹ 133.71 crore to ₹ 131.22 crore over 2 quarters. This represents a CAGR of -3.69% The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Sotac Pharmaceuticals Ltd is ₹ 25.5 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Sotac Pharmaceuticals Ltd is ₹ 2.46 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Sotac Pharmaceuticals Ltd is ₹ 1.35 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Sotac Pharmaceuticals Ltd changed from 13.94 % to 0 % over 4 quarters. This represents a CAGR of -100.00% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015.
Thereafter 'M/s.
Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat.
Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad. The Company is a part of SOTAC Group, based at Gujarat and is engaged in manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis.

FAQs for the comparison of Sanofi India Ltd and Sotac Pharmaceuticals Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Sotac Pharmaceuticals Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Sotac Pharmaceuticals Ltd is 129 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Sotac Pharmaceuticals Ltd?

The stock performance of Sanofi India Ltd and Sotac Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Sotac Pharmaceuticals Ltd?

As of May 3, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Sotac Pharmaceuticals Ltd stock price is INR ₹117.0.

How do dividend payouts of Sanofi India Ltd and Sotac Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Sotac Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.